Sequence 4

DRUG5 trials

Sponsors

Yuhan Corporation, Samyang Biopharmaceuticals Corporation, University of Colorado, Denver, Chong Kun Dang Pharmaceutical, JHM BioPharma (Tonghua) Co. , Ltd.

Conditions

DyslipidemiasHealthyHyperlipidemiaHypertensionUpper Limb SpasticityWillpower

Phase 1

Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects

CompletedNCT01332890

Yuhan CorporationHealthy

Start: 2011-04-30End: 2011-08-31Updated: 2014-07-10

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

CompletedNCT01353404

Samyang Biopharmaceuticals CorporationHyperlipidemia

Start: 2011-06-30End: 2011-08-31Updated: 2012-12-18

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

Chong Kun Dang PharmaceuticalDyslipidemias, Hypertension

Start: 2018-08-31End: 2019-01-15Target: 30Updated: 2018-11-01

A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity

CompletedNCT06584240

JHM BioPharma (Tonghua) Co. , Ltd.Upper Limb Spasticity

Start: 2024-09-14End: 2025-07-23Updated: 2025-09-02

Unknown Phase

A Pilot Study: Snacking, Willpower and Glucose Availability

CompletedNCT02258477

University of Colorado, DenverWillpower

Start: 2014-10-31End: 2015-02-28Updated: 2016-03-04